COVID-19 in Immunocompromised Participants

COVID-19 in Immunocompromised Participants
A participant who is immunocompromised has an immune system that is less likely to effectively fight viral infections. This clinical study is evaluating if a longer treatment (10 or 15 days) with the study drug will be more effective and yet, still safe compared to the standard 5-day treatment in such participants.
Mode of administration:
2 Tablets orally
The study duration: 24 Weeks
Participants will attend approximately 10 study site visits and receive follow-up checks following the completion of the study.
Compensation package includes:
$150 for each visit to study site
All study medication, assessments and examinations are free to the participants.
Inclusion Questions:
Has the patient tested positive for COVID-19?
Is the patient immunocompromised?
What medical condition does the patient have?
Patient’s other medical conditions: